ERBB2 and breast cancer: In HER2-positive (HER2+) advanced BC (ABC), the recommended first-line treatment is the combination of HER2-targeted therapy (trastuzumab + pertuzumab) with taxane chemotherapy (docetaxel or paclitaxel), regardless of ER status [7].